{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:07:25Z","timestamp":1789578445944,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hailey-Hailey disease (HHD) is a rare autosomal dominantly inherited skin disorder first described by brothers Howard and Hugh Hailey in 1939. This article reports a case of refractory Hailey-Hailey disease, which was treated with upadacitinib with remarkable efficacy after the unsatisfactory results of traditional treatment regimens. The patient was a 38-year-old male with a 2-year history of the disease. The rash improved significantly at 3 weeks of oral treatment with upadacitinib 15 mg\/day and continued to improve at 12 weeks of follow-up without serious adverse effects. Together with the literature review, this study aims to investigate the efficacy and safety of the JAK inhibitor upadacitinib as a novel therapeutic regimen for Hailey-Hailey disease, and to provide a reference for the clinical treatment of refractory cases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1676459","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:31:27Z","timestamp":1768372287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib successfully treats Hailey-Hailey disease: a cases report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhuochen","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Technical Innovation Center of Dermatology and Medical Cosmetology Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Technical Innovation Center of Dermatology and Medical Cosmetology Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Technical Innovation Center of Dermatology and Medical Cosmetology Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Technical Innovation Center of Dermatology and Medical Cosmetology Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Subcenter of National Clinical Research Center for Skin and Immune Diseases","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Technical Innovation Center of Dermatology and Medical Cosmetology Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40257-019-00477-z","article-title":"Hailey-hailey disease: an update review with a focus on treatment data","volume":"21","author":"Ben Lagha","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2006.00303.x","article-title":"Fitzpatrick's color atlas and synopsis of clinical dermatology","volume":"47","author":"Dyall-Smith","year":"2025","journal-title":"Australas J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.09.011","article-title":"Refractory Hailey-Hailey disease cleared with upadacitinib","volume":"41","author":"Murphy","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164608","article-title":"Therapeutic maintenance of janus kinase inhibitors in real life for rheumatoid arthritis: retrospective study","volume":"13","author":"Farnos","year":"2024","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"LANCET"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-017-2544-7","article-title":"The role of the ATP2C1 gene in Hailey-Hailey disease","volume":"74","author":"Deng","year":"2017","journal-title":"CMLS-CELL Mol Life S"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67227","article-title":"Hailey-hailey disease successfully treated with adalimumab: A case series","volume":"16","author":"Alicea-Negr\u00f3n","year":"2024","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.10278169","article-title":"Hailey-Hailey disease: A case report","volume":"62","author":"Rodr\u00edguez-Guti\u00e9rrez","year":"2024","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"B9","first-page":"92","article-title":"Enfermedad de Hailey-Hailey: presentaci\u00f3n de dos casos","volume":"96","author":"Halac","year":"2015","journal-title":"Rev Argent Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.039","article-title":"Interventional treatments for Hailey-Hailey disease","volume":"76","author":"Farahnik","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2191","article-title":"Treatment of severe hailey-hailey disease with apremilast","volume":"154","author":"Kieffer","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.09.014","article-title":"Adalimumab therapy used successfully for recalcitrant Hailey-Hailey disease","volume":"29","author":"Chen","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1220887","article-title":"Janus kinase inhibitors in autoimmune bullous diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028555","article-title":"Responses to cytokines and interferons that depend upon JAKs and STATs","volume":"10","author":"Stark","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.12.026","article-title":"SMOC1 and IL-4 and IL-13 cytokines interfere with ca2+ Mobilization in primary human keratinocytes","volume":"141","author":"Lyubchenko","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X251350332","article-title":"Treatment of Hailey-Hailey disease with the Janus kinase inhibitor abrocitinib: A case report","volume":"13","author":"Gunyon","year":"2025","journal-title":"SAGE Open Med Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad023","article-title":"Improvement of Hailey-Hailey disease with abrocitinib","volume":"48","author":"Li","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2493936","article-title":"Tofacitinib as a promising treatment for refractory erythroderma-like Hailey-Hailey disease","volume":"36","author":"Bao","year":"2025","journal-title":"J Dermatol Treat"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcae149","article-title":"Treatment of Hailey-Hailey disease with Janus kinase inhibitorss","volume":"117","author":"Cui","year":"2024","journal-title":"QJM: monthly J Assoc Physicians"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e62701","DOI":"10.7759\/cureus.62701","article-title":"Treatment of recalcitrant hailey-hailey disease with naltrexone and dupilumab: A report of two cases","volume":"16","author":"Santoso","year":"2024","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.10.004","article-title":"Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab","volume":"42","author":"Khang","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.09.019","article-title":"Successful Treatment of Hailey-Hailey Disease With Dupilumab. [Art\u00edculo traducido] Tratamiento exitoso de la enfermedad de Hailey-Hailey con dupilumab","volume":"114","author":"Brito Caldeira","year":"2023","journal-title":"Actas dermo-sifiliograficas"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16322","article-title":"A case of Hailey-Hailey disease successfully treated with dupilumab","volume":"61","author":"Licata","year":"2022","journal-title":"Int J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18350","article-title":"Dupilumab in Hailey-Hailey disease: a case series","volume":"36","author":"Alamon-Reig","year":"2022","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20475","article-title":"Hailey-Hailey disease treated with dupilumab: a case series","volume":"185","author":"Alzahrani","year":"2021","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract15030048","article-title":"Dupilumab, a potential novel treatment for hailey-hailey disease","volume":"15","author":"Popa","year":"2025","journal-title":"Clinics Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:39:07Z","timestamp":1771911547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2025.1676459"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1676459","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1676459"}}